A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management



: Andersson Nadine G, Rathe Mathias, Molle Ingolf, Jarvis Kirsten Brunswig, Hoffmann Marianne, Huurre Anu, Joelsson Joel, Albertsen Birgitte K, Lohi Olli, Långström Satu, Overgaard Ulrik, Trakymiene Sonata Saulyte, Vepsäläinen Kaisa, Vogt Harmut, Ranta Susanna

Publisher: WILEY

: 2022

: British Journal of Haematology

: BRITISH JOURNAL OF HAEMATOLOGY

: BRIT J HAEMATOL

: 199

: 1

: 117

: 121

: 5

: 0007-1048

: 1365-2141

DOI: https://doi.org/10.1111/bjh.18397

: https://doi.org/10.1111/bjh.18397

: https://research.utu.fi/converis/portal/detail/Publication/176233766


Patients undergoing treatment for acute lymphoblastic leukaemia (ALL) are at risk of coagulopathy, especially thromboembolism. We conducted a survey on practices in the assessment and management of coagulopathy during the new ALLTogether protocol in 29 (17 paediatric, 12 adult) Nordic and Baltic cancer centres. While 92% of adult centres used thromboprophylaxis with low-molecular-weight heparin, no paediatric centre did. Almost all providers performed baseline coagulation studies, but only 59% continued the assessment. Fibrinogen replacement was conducted in 59%, and antithrombin replacement in 28% of the centres. The survey highlights the need for guidelines in the management of coagulopathy during ALL therapy.

Last updated on 2024-26-11 at 13:50